Compendium of Cancer Genome Aberrations

STBT5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
Kathleen.Schieffer (talk | contribs)
autoreview, editor
141 edits
No edit summary
Kathleen.Schieffer (talk | contribs)
autoreview, editor
141 edits
No edit summary
 
(36 intermediate revisions by 2 users not shown)
Line 160: Line 160:
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]]
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]]
|Disease
|Disease
|Kauser Begum Ravishankar (trainee), with Katie
|2/25/2026
|5/25/2026
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
|
Line 182: Line 182:
|[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]]
|[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]]
|Disease
|Disease
|Karla Sofía Peláez Valdés (trainee);
Katie Schieffer (mentor)
|3/1/2026
|
|
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
Line 229: Line 230:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]]
|[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]]
Line 423: Line 424:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|No genetic association
|-
|-
|[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]]
|[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]]
Line 453: Line 454:
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]]
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]]
|Disease
|Disease
|Kate Schieffer
|Katie Schieffer
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]]
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]]
Line 497: Line 498:
|[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]]
|[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]]
|Disease
|Disease
|He Fang
|2/19/2026
|5/20/2026
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
|
Line 521: Line 522:
|9/24/2025
|9/24/2025
|12/24/2025
|12/24/2025
|PENDING
|COMPLETE
|
|12/18/2025
|
|Katie Schieffer
|
|12/18/2025
|
|
|-
|-
|[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]]
|[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]]
|Disease
|Disease
|
|Katherine Geiersbach
|
|8/11/2023
|
|11/11/2203
|
|COMPLETE
|
|1/8/2025
|
|Katherine Geiersbach
|
|1/8/2025
|
|
|-
|-
Line 543: Line 544:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]]
|[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]]
Line 562: Line 563:
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]]
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]]
|Disease
|Disease
|
|Mokhtar Abdelhammed, MD (trainee);
|
Katie Schieffer (mentor)
|
|3/1/2026
|
|6/30/2026
|
|COMPLETE
|
|3/3/2026
|
|Katie Schieffer
|3/4/2026
|
|
|-
|-
Line 662: Line 664:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|No genetic association
|-
|-
|[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]]
|[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]]
Line 673: Line 675:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Synovial_haemangioma|Synovial haemangioma]]
|[[STBT5:Synovial_haemangioma|Synovial haemangioma]]
Line 684: Line 686:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/10/2025
|
|Katie Schieffer
|
|11/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Intramuscular_angioma|Intramuscular angioma]]
|[[STBT5:Intramuscular_angioma|Intramuscular angioma]]
Line 695: Line 697:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]]
|[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]]
Line 717: Line 719:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]]
|[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]]
Line 781: Line 783:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]]
|[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]]
Line 792: Line 794:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]]
|[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]]
Line 911: Line 913:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]]
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]]
Line 1,016: Line 1,018:
|[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]]
|[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]]
|Disease
|Disease
|Shanmugapriya Veeralakumar (trainee); Katie as mentor
|2/23/2026
|
|
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
Line 1,096: Line 1,098:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|No genetic association
|-
|-
|-
|-
Line 1,116: Line 1,118:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|12/11/2025
|Katie Schieffer
|12/11/2025
|No genetic association
|-
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]]
|Disease
|Katie Schieffer
|9/21/2025
|12/21/2025
|PENDING
|
|
|
|
Line 1,191: Line 1,193:
|Disease
|Disease
|Katie Schieffer
|Katie Schieffer
|921/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]]
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]]
|Disease
|Disease
|
|
|
|
Line 1,265: Line 1,267:
|[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]]
|[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]]
|Disease
|Disease
|Mokhtar Abdelhammed, MD
|Mokhtar Abdelhammed, MD (trainee);
Katie Schieffer (mentor)
|9/11/2025
|9/11/2025
|12/11/2025
|12/11/2025
|PENDING
|COMPLETE
|
|12/29/2026
|Katie Schieffer
|Katie Schieffer
|
|1/7/2026
|
|
|-
|-
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]]
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]]
|Disease
|Disease
|
|Mokhtar Abdelhammed, MD (trainee);
|
Katie Schieffer (mentor)
|
|3/1/2026
|
|6/30/2026
|PENDING
|
|
|
|
Line 1,301: Line 1,305:
|2/20/2022
|2/20/2022
|12/9/2025
|12/9/2025
|PENDING
|COMPLETE
|
|2/26/2026
|Katie Schieffer
|Katie Schieffer
|
|2/26/2026
|
|
|-
|-
Line 1,334: Line 1,338:
|10/13/2025
|10/13/2025
|12/31/2025
|12/31/2025
|PENDING
|COMPLETE
|
|12/24/2025
|Katie Schieffer
|Katie Schieffer
|
|12/24/2025
|
|
|-
|-
Line 1,373: Line 1,377:
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]]
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]]
|Disease
|Disease
|Maxine Sutcliffe, PhD
|1/12/2026
|4/12/2026
|PENDING
|
|
|
|
|
|
|
|
|
|-
|
|
|
|-
|[[STBT5:Extrarenal_rhabdoid_tumour|Extrarenal rhabdoid tumour]]
|[[STBT5:Extrarenal_rhabdoid_tumour|Extrarenal rhabdoid tumour]]
|Disease
|Disease
Line 1,449: Line 1,453:
|[[STBT5:Ewing_sarcoma|Ewing sarcoma]]
|[[STBT5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|Disease
|Sadeem Qdaisat
|Sadeem Qdaisat (trainee); Eric McGinnis (mentor)
|10/1/23
|10/1/2023
|12/9/2025
|12/9/2025
|PENDING
|PENDING
|
|
|Working with Eric McGinnis
|Katie Schieffer
|
|
|
|2021 template added
|-
|-
|[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]]
|[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]]
Line 1,482: Line 1,486:
|[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]]
|[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]]
|Disease
|Disease
|He Fang
|2/19/2026
|8/20/2026
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
|
Line 1,526: Line 1,530:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]]
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]]
Line 1,537: Line 1,541:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
<br />
|12/8/2025
|Katie Schieffer
|12/8/2025
|
|-
|[[STBT5:Periosteal_chondroma|Periosteal chondroma]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[STBT5:Periosteal_chondroma|Periosteal chondroma]]
|Disease
|Katie Schieffer
|9/21/2025
|12/21/2025
|PENDING
|
|
|
|
Line 1,557: Line 1,560:
|[[STBT5:Enchondroma|Enchondroma]]
|[[STBT5:Enchondroma|Enchondroma]]
|Disease
|Disease
|Katie Schieffer
|
|9/21/2025
|
|12/21/2025
|
|PENDING
|
|
|
|
|
Line 1,568: Line 1,571:
|[[STBT5:Osteochondroma|Osteochondroma]]
|[[STBT5:Osteochondroma|Osteochondroma]]
|Disease
|Disease
|Katie Schieffer
|
|9/21/2025
|
|12/21/2025
|
|PENDING
|
|
|
|
|
Line 1,582: Line 1,585:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|
|-
|-
Line 1,625: Line 1,628:
|Katie Schieffer
|Katie Schieffer
|9/21/2025
|9/21/2025
|12/21/2025
|12/31/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|
|-
|-
Line 1,773: Line 1,776:
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|Disease
|Disease
|Fang Fang (trainee); Katie Schieffer (mentor)
|11/19/2025
|4/15/2026
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
|
Line 1,853: Line 1,856:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association
|-
|-
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]]
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]]
|Disease
|Disease
|[[STBT5:Epithelioid haemangioma|See STBT5: Epithelioid haemangioma page]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]]
|
|
|
|
|
|-
|[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]]
|Disease
|Disease
|
|[[STBT5:Epithelioid haemangioendothelioma|See STBT5: Epithelioid haemangioendothelioma page]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,891: Line 1,894:
|-
|-
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
|Disease
|[[STBT5:Angiosarcoma|See STBT5: Angiosarcoma page]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[STBT5:Aneurysmal_bone_cyst|Aneurysmal bone cyst]]
|Disease
|Disease
|
|
Line 1,900: Line 1,914:
|
|
|
|
|-
|[[STBT5:Aneurysmal_bone_cyst|Aneurysmal bone cyst]]
|Disease
|
|
|
|
|
|
|
|
|-
|-
|[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]]
|[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]]
Line 1,961: Line 1,964:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association, early genetic studies referenced
|-
|-
|[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]]
|[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]]
Line 1,983: Line 1,986:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association
|-
|-
|[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]]
|[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]]
Line 1,994: Line 1,997:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|10/22/2025
|Katie Schieffer
|10/22/2025
|
|
|
|-
|
|
|-
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
Line 2,055: Line 2,058:
|[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]]
|[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]]
|Disease
|Disease
|Katie Schieffer
|
|9/21/2025
|
|12/21/2025
|
|PENDING
|
|
|
|
|
Line 2,066: Line 2,069:
|[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]]
|[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]]
|Disease
|Disease
|Katie Schieffer
|[[STBT5:Leiomyosarcoma|See STBT5: Leiomyosarcoma page]]
|9/21/2025
|N/A
|12/21/2025
|N/A
|PENDING
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]]
|[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]]
|Disease
|Disease
|Maxine Sutcliffe
|2/23/2026
|4/12/2026
|COMPLETE
|4/27/2026
|Katie Schieffer
|4/28/2026
|
|
|
|-
|
|
|
|
|
|
|-
|[[STBT5:Bone_metastases|Bone metastases]]
|[[STBT5:Bone_metastases|Bone metastases]]
|Disease
|Disease
Line 2,099: Line 2,102:
|[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]]
|[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]]
|Disease
|Disease
|Katie Schieffer
|9/21/2025
|12/21/2025
|PENDING
|
|
|
|
|
|
|Refer to plasmacytoma page in heme book
|
|
|
|
|
|-
|-
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]]
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]]
Line 2,130: Line 2,133:
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]]
|[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 2,184: Line 2,187:
|[[STBT5:Enchondromatosis|Enchondromatosis]]
|[[STBT5:Enchondromatosis|Enchondromatosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 2,202: Line 2,205:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]]
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]]
|[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 2,235: Line 2,238:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]]
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[STBT5:Werner_syndrome|Werner syndrome]]
|[[STBT5:Werner_syndrome|Werner syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|}<br />
|}<br />
Retrieved from "https://content.ccga.io/index.php/STBT5:Volunteer_Assignments_and_Opportunities"